Greenblum & Bernstein's P. Branko Pejic and Jill M. Browning to Speak at the Knowledge Group’s Strategic Patent Portfolio and Lifecycle Development Event
Greenblum & Bernstein, P.L.C. Partners P. Branko Pejic and Jill M. Browning to Speak at the Knowledge Group’s Strategic Patent Portfolio and Lifecycle Development for Pharma & Biotech Industries in 2016 Live Webcast.
New York, NY, January 18, 2016 --(PR.com)-- The Knowledge Group/The Knowledge Congress Live Webcast Series, the leading producer of regulatory focused webcasts, has announced today that P. Branko Pejic and Jill M. Browning, Partners with Greenblum & Bernstein, P.L.C. will speak at the Knowledge Group’s webcast entitled: “Strategic Patent Portfolio and Lifecycle Development for Pharma & Biotech Industries in 2016.” This event is scheduled for March 31, 2016 from 12:00pm – 2:00pm (ET).
For further details, please visit: https://theknowledgegroup.org/strategic-patent-portfolio-and-lifecycle-development-for-pharma-biotech-industries-in-2016-live-webcast-2/
About Jill M. Browning
Jill M. Browning is a partner with Greenblum & Bernstein. She holds a bachelor of science from the University of Virginia in chemistry with a specialization in biochemistry as well as a law degree from the University of Virginia School of Law. After graduating, Ms. Browning clerked for the “Rocket Docket” otherwise known as the U.S. District Court for the Eastern District of Virginia. Currently, Ms. Browning’s practice focusses on contested matters before the U.S. Patent and Trademark Office as well as patent litigations in U.S. District Courts, including Hatch-Waxman ANDA litigations. She has both first and second chair experience at trial and has argued many cases before the U.S.P.T.O. Patent Trial and Appeal Board. Ms. Browning has also negotiated and drafted numerous IP agreements and routinely counsels clients on managing their patent portfolio.
About P. Branko Pejic
Mr. Pejic is a partner in Greenblum & Bernstein’s litigation and trial practice group. Prior to joining the firm in 1999, Mr. Pejic clerked for U.S. District Court Judge H. Dale Cook in the Northern District of Oklahoma, and since then, he routinely litigates Hatch-Waxman ANDA litigations in U.S. District Courts country-wide; most recently invalidating a patent for a blockbuster drug in a bench trial in Delaware. Mr. Pejic has also argued appeals before the Court of Appeals for the Federal Circuit, advised clients on patent portfolio management matters, and been involved in negotiations for acquisition, sale and in/out licensing of patent portfolios, as part of transactions involving pharmaceutical patents, business divisions and products. He has also spoken on patent valuation and monetization. Mr. Pejic holds a bachelor of science in Chemical Engineering from the University of Arkansas, a J.D. from the University of Tulsa and an LLM in International and Comparative Law (with focus on international trade and intellectual property protection) from the Georgetown University Law Center.
About Greenblum & Bernstein, P.L.C.
Greenblum & Bernstein specializes exclusively in intellectual property law, particularly concentrating in patents, trademarks and copyrights. G&B maintains an active docket in all aspects and stages of intellectual property practice surrounding the life sciences (both biotechnology and pharmaceuticals), including patent prosecution and licensing, post-grant procedures, interferences, derivation proceedings, litigation, and Hatch-Waxman.
Event Synopsis:
The relentless transformation of generic competition seems to pose a threat for pharma and biotech lifecycles. With its growing complexity, companies with poor product lifecycle management strategies are more likely to be exposed to legal challenges and revenue risks. Thus, it is crucial for companies to establish and maintain a robust life cycle management strategy to minimize possible loss and liabilities.
In a two-hour live Webcast, a panel of key thought leaders, professionals and regulators assembled by The Knowledge Group will help the audience understand the most significant issues with respect to portfolio strategies in pharmaceutical and biotechnology patent lifecycle management and development. The panel will also share their expertise and insights on how to best maintain an effective and efficient patent portfolio in biotech and pharma lifecycle.
Key topics include:
− Pharmaceutical and Biotechnology Patent Life Cycles – An Overview
− Patent Term Adjustments for Biotech and Pharma
− Role of PTA in Biotech and Pharma Patent Life Cycle
− Patent Term Extensions
− Patentability and Implications for Life Sciences Innovation
− Portfolio Strategies
− Common Risks and Pitfalls
− Up-to-the-minute Regulatory Updates
About The Knowledge Group/The Knowledge Congress Live Webcast Series
The Knowledge Group was established with the mission to produce unbiased, objective, and educational live webinars that examine industry trends and regulatory changes from a variety of different perspectives. The goal is to deliver a unique multilevel analysis of an important issue affecting business in a highly focused format. To contact or register for an event, please visit: http://theknowledgegroup.org/
For further details, please visit: https://theknowledgegroup.org/strategic-patent-portfolio-and-lifecycle-development-for-pharma-biotech-industries-in-2016-live-webcast-2/
About Jill M. Browning
Jill M. Browning is a partner with Greenblum & Bernstein. She holds a bachelor of science from the University of Virginia in chemistry with a specialization in biochemistry as well as a law degree from the University of Virginia School of Law. After graduating, Ms. Browning clerked for the “Rocket Docket” otherwise known as the U.S. District Court for the Eastern District of Virginia. Currently, Ms. Browning’s practice focusses on contested matters before the U.S. Patent and Trademark Office as well as patent litigations in U.S. District Courts, including Hatch-Waxman ANDA litigations. She has both first and second chair experience at trial and has argued many cases before the U.S.P.T.O. Patent Trial and Appeal Board. Ms. Browning has also negotiated and drafted numerous IP agreements and routinely counsels clients on managing their patent portfolio.
About P. Branko Pejic
Mr. Pejic is a partner in Greenblum & Bernstein’s litigation and trial practice group. Prior to joining the firm in 1999, Mr. Pejic clerked for U.S. District Court Judge H. Dale Cook in the Northern District of Oklahoma, and since then, he routinely litigates Hatch-Waxman ANDA litigations in U.S. District Courts country-wide; most recently invalidating a patent for a blockbuster drug in a bench trial in Delaware. Mr. Pejic has also argued appeals before the Court of Appeals for the Federal Circuit, advised clients on patent portfolio management matters, and been involved in negotiations for acquisition, sale and in/out licensing of patent portfolios, as part of transactions involving pharmaceutical patents, business divisions and products. He has also spoken on patent valuation and monetization. Mr. Pejic holds a bachelor of science in Chemical Engineering from the University of Arkansas, a J.D. from the University of Tulsa and an LLM in International and Comparative Law (with focus on international trade and intellectual property protection) from the Georgetown University Law Center.
About Greenblum & Bernstein, P.L.C.
Greenblum & Bernstein specializes exclusively in intellectual property law, particularly concentrating in patents, trademarks and copyrights. G&B maintains an active docket in all aspects and stages of intellectual property practice surrounding the life sciences (both biotechnology and pharmaceuticals), including patent prosecution and licensing, post-grant procedures, interferences, derivation proceedings, litigation, and Hatch-Waxman.
Event Synopsis:
The relentless transformation of generic competition seems to pose a threat for pharma and biotech lifecycles. With its growing complexity, companies with poor product lifecycle management strategies are more likely to be exposed to legal challenges and revenue risks. Thus, it is crucial for companies to establish and maintain a robust life cycle management strategy to minimize possible loss and liabilities.
In a two-hour live Webcast, a panel of key thought leaders, professionals and regulators assembled by The Knowledge Group will help the audience understand the most significant issues with respect to portfolio strategies in pharmaceutical and biotechnology patent lifecycle management and development. The panel will also share their expertise and insights on how to best maintain an effective and efficient patent portfolio in biotech and pharma lifecycle.
Key topics include:
− Pharmaceutical and Biotechnology Patent Life Cycles – An Overview
− Patent Term Adjustments for Biotech and Pharma
− Role of PTA in Biotech and Pharma Patent Life Cycle
− Patent Term Extensions
− Patentability and Implications for Life Sciences Innovation
− Portfolio Strategies
− Common Risks and Pitfalls
− Up-to-the-minute Regulatory Updates
About The Knowledge Group/The Knowledge Congress Live Webcast Series
The Knowledge Group was established with the mission to produce unbiased, objective, and educational live webinars that examine industry trends and regulatory changes from a variety of different perspectives. The goal is to deliver a unique multilevel analysis of an important issue affecting business in a highly focused format. To contact or register for an event, please visit: http://theknowledgegroup.org/
Contact
The Knowledge Group
Thomas LaPointe, Jr., Executive Director
646-844-0200
www.theknowledgegroup.org
Therese Lumbao, Director
Account Management & Member Services
tlumbao@knowledgecongress.org
Thomas LaPointe, Jr., Executive Director
646-844-0200
www.theknowledgegroup.org
Therese Lumbao, Director
Account Management & Member Services
tlumbao@knowledgecongress.org
Contact
Categories